BioCentury | Feb 26, 2021
Management Tracks

Ziopharm CEO stepping down; plus moves at ChemoCentryx, ReForm, Monte Rosa and Enterin

...announcement comes as ChemoCentryx looks ahead to a July 7 PDUFA date for vasculitis therapy avacopan.Protein therapeutics...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...for clinical development, manufacturing and commercialization. Developed with the company’s variant immunoglobulin domain technology, Alpine’s protein therapeutics...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

...Phase III trials. COMPANY PROFILE Sichuan Clover Biopharmaceuticals Inc. Chengdu, China Technology: Covalently trimerized fusion protein therapeutics...
BioCentury | Apr 9, 2020
Finance

Keros rises 26% in trading debut during week of market gains

Keros priced an upsized IPO Wednesday and gained $4.08 (26%) to $20.08 despite continued pandemic-driven volatility in the markets. While the Arca NYSE Biotechnology (BTK) and NASDAQ Biotechnology (NBI) and the S&P Biotech ETF (XBI)...
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...succeeds Chip Marshall, who remains as COO. The company, which is developing analytic tools for protein therapeutics...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

...the broader population. And another group is using gene therapy to bypass delivery limitations of protein therapeutics...
BioCentury | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

...down from her position effective July 1 and will become a strategic consultant for the protein therapeutics...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Biodiscovery, Quan Capital, Quan Ventures, Sofinnova Partners, IP Group, EMBL Ventures, Takeda Ventures Inc. Small protein therapeutics...
Items per page:
1 - 10 of 443
BioCentury | Feb 26, 2021
Management Tracks

Ziopharm CEO stepping down; plus moves at ChemoCentryx, ReForm, Monte Rosa and Enterin

...announcement comes as ChemoCentryx looks ahead to a July 7 PDUFA date for vasculitis therapy avacopan.Protein therapeutics...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...for clinical development, manufacturing and commercialization. Developed with the company’s variant immunoglobulin domain technology, Alpine’s protein therapeutics...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

...Phase III trials. COMPANY PROFILE Sichuan Clover Biopharmaceuticals Inc. Chengdu, China Technology: Covalently trimerized fusion protein therapeutics...
BioCentury | Apr 9, 2020
Finance

Keros rises 26% in trading debut during week of market gains

Keros priced an upsized IPO Wednesday and gained $4.08 (26%) to $20.08 despite continued pandemic-driven volatility in the markets. While the Arca NYSE Biotechnology (BTK) and NASDAQ Biotechnology (NBI) and the S&P Biotech ETF (XBI)...
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...succeeds Chip Marshall, who remains as COO. The company, which is developing analytic tools for protein therapeutics...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

...the broader population. And another group is using gene therapy to bypass delivery limitations of protein therapeutics...
BioCentury | Jun 11, 2019
Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

...down from her position effective July 1 and will become a strategic consultant for the protein therapeutics...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Biodiscovery, Quan Capital, Quan Ventures, Sofinnova Partners, IP Group, EMBL Ventures, Takeda Ventures Inc. Small protein therapeutics...
Items per page:
1 - 10 of 443